Adamas Pharmaceuticals, Inc.
1900 Powell Street
Suite 1050
Emeryville
California
94608
United States
Tel: 510-450-3500
Fax: 510-428-0519
Website: http://www.adamaspharma.com/
Email: info@adamaspharma.com
About Adamas Pharmaceuticals, Inc.
200 articles about Adamas Pharmaceuticals, Inc.
-
ADAMA to Acquire AgriNova New Zealand Ltd.
12/6/2022
ADAMA Ltd., a leading global crop protection company, announced the acquisition of AgriNova New Zealand, Ltd – known as Grochem New Zealand.
-
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals
11/24/2021
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS).
-
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer
11/23/2021
Supernus Pharmaceuticals, Inc. announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Supernus’ proposed acquisition of Adamas Pharmaceuticals, Inc. expired at 11:59 p.m. on November 22, 2021.
-
Shares of Adamas Pharmaceuticals are up nearly 75% this morning after Supernus Pharmaceuticals announced it was acquiring the company and its Parkinson’s disease products.
-
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
10/11/2021
Supernus Pharmaceuticals, Inc. and Adamas Pharmaceuticals, Inc., announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash, payable at closing plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash, for a total consideration of $9.10 per share in cash.
-
Adamas Announces New Employment Inducement Grants - Oct 08, 2021
10/8/2021
Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted eight new employees restricted stock units to acquire 106,500 shares of the company’s common stock.
-
Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society’s (MDS) Congress
9/16/2021
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, taking place September 17 – 22, 2021.
-
Adamas Announces New Employment Inducement Grants
9/10/2021
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven new employees restricted stock units to acquire 94,750 shares of the company’s common stock.
-
Adamas to Present at Upcoming September Investor Conferences
8/30/2021
Adamas Pharmaceuticals, Inc. today announced that management will present at the virtual investor conferences during the month of September 2021
-
Adamas Announces New Employment Inducement Grant - Aug 13, 2021
8/13/2021
Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted three new employees restricted stock units to acquire 38,500 shares of the company’s common stock.
-
Adamas Reports Second Quarter 2021 Financial Results
8/9/2021
Adamas Pharmaceuticals, Inc., a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, reported financial results for the second quarter ended June 30, 2021, and recent corporate highlights.
-
Adamas to Announce Second Quarter Financial Results and Host Conference Call on August 9, 2021
8/2/2021
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report second quarter 2021 financial results on Monday, August 9, after market close.
-
Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101
7/22/2021
Adamas Pharmaceuticals, Inc. today announces the issuance of two patents covering GOCOVRI® (amantadine) extended-release capsules: U.S. Patent No. 11,065,213 issued on July 20, 2021, and U.S. Patent No. 11,077,073, projected to issue on August 3, 2021.
-
Adamas Announces New Employment Inducement Grant - July 09, 2021
7/9/2021
Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted four new employees restricted stock units to acquire 44,500 shares of the company’s common stock.
-
Adamas to Present at Upcoming William Blair Biotech Focus Conference
7/8/2021
Adamas Pharmaceuticals, Inc., a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 1:00 pm Eastern Time.
-
Adamas to Present at Upcoming SVB Leerink CNS Forum
6/23/2021
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the company will present “What’s Happening in Parkinson’s Disease & the GOCOVRI Opportunity” at the SVB Leerink CNS Forum
-
Adamas Announces New Employment Inducement Grant - June 11, 2021
6/11/2021
Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted three new employees restricted stock units to acquire 22,500 shares of the company’s common stock.
-
New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson’s Disease
6/10/2021
Adamas Pharmaceuticals, Inc. announced the publication of a new data analysis titled, “Effects of GOCOVRI® extended-release capsules on motor aspects of experiences of daily living in people with Parkinson’s disease and dyskinesia” in the peer-reviewed journal of Neurology and Therapy.
-
Adamas to Present at Upcoming June Conferences
5/27/2021
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the organization will be participating in two upcoming June conferences:
-
Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call
5/17/2021
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be held on Monday, May 17, 2021, at 2 p.m. Pacific Time.